Zhitong Finance App learned that on January 8, 2024, the General Office of the Ministry of Industry and Information Technology and the General Office of the State Council's State-owned Assets Administration Commission jointly released the 2023 “one-stop” application demonstration and promotion agency list for key products and processes, and Yongtai Bio-B (06978) was successfully selected as the recommended agency for the key application of “activated autolymphocyte activated products”.

The Ministry of Industry and Information Technology and the State Council's State-owned Assets Administration Commission jointly organized and carried out the 2023 “one-stop” application demonstration work for key products and processes. The aim is to focus on key application directions in cutting-edge fields such as novel materials, intelligent manufacturing, and cell therapy, accelerate the promotion and application of high-quality basic products and advanced processes, and focus on solving the problem of “not easy to use, afraid to use”.

This time, out of the 36 application demonstration directions selected, more than 40 organizations from all over the country were successfully selected for the 2023 “one-stop” application demonstration direction list for key products and processes. Yongtai Biotech is the only cell therapy company selected. Yongtai Biotech's successful selection fully proved that its technical research and development capabilities, industrialization capabilities, and ability to integrate upstream and downstream industrial chains in the field of immunocyte therapy have been highly recognized by national ministries and departments. At the same time, the successful finalization and smooth promotion of the project will provide a new solution for China to establish a large-scale independent production and supply system for immunocyte drugs, fill the supply gap in the domestic industrial chain, and use the Yongtai Biological Immune Cell Drug Industrialization Project as an implementation carrier, which can be quickly transformed into other related cell products to benefit, promote the level and maturity of China's immune cell drug industry, and meet the industrialization needs for transformation into other similar cell products.

Yongtai Biotech will use being selected as a “one-stop” application demonstration recommendation agency as a new opportunity to continue to adhere to the spirit of innovation, collaboration and pragmatism, deepen industry-academia research and use cooperation, increase key core technology research, and work with Jinzhou Medical University, Peking University, Shenzhen Shenyan Biotechnology Co., Ltd., Chutian Si Wei Kang Gene Technology (Changsha) Co., Ltd., Suzhou Weidu Biotechnology Co., Ltd., Huzhou Shenke Biotechnology Co., Ltd., Dongfulong Life Technology Co., Ltd., and Shanghai Zhimi Pharmaceutical Technology Co., Ltd., to jointly promote technological innovation of autolymphocyte-activated products With application development, we strive to create an industrial pattern of “integration of industry, education, research and use, mutual integration and symbiosis of upstream and downstream industrial chains, and collaborative innovation”, making greater contributions to the construction of a healthy China.